Neurogenetics Announces Name Change to TorreyPines Therapeutics

Neurogenetics, a clinical-stage biopharmaceutical company focused on discovering and developing breakthrough small molecule drugs to treat diseases and disorders of the central nervous system, has changed its name to TorreyPines Therapeutics. The company also reported it has completed a $34.8 million Series C financing to advance its product development programs in migraine and Alzheimer's disease.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19402020&full=1)